# Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

> **NCT00753896** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 134 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** exenatide

## Key facts

- **NCT ID:** NCT00753896
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-11
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2015-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753896, "Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00753896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*